

Company Announcement

12 September 2011

Novo Nordisk A/S – Share repurchase programme

On 11 August 2011 Novo Nordisk initiated a share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.

Under the programme Novo Nordisk will repurchase B shares for an amount up to DKK 2.1 billion in the period from 11 August 2011 to 25 October 2011.

Since the announcement as of 5 September 2011, the following transactions have been made under the programme:

	Number of shares	Average purchase price	Transaction value, DKK
Accumulated, last announcement	1,165,000		637,193,409
5 September 2011	70,000	543.3429	38,034,003
6 September 2011	65,000	546.2800	35,508,200
7 September 2011	65,000	557.2700	36,222,550
8 September 2011	65,000	573.0700	37,249,550
9 September 2011	65,000	560.5500	36,435,750
Accumulated under the programme	1,495,000		820,643,462

With the transactions stated above, Novo Nordisk owns a total of 19,886,697 treasury shares, corresponding to 3.4% of the share capital. The total amount of shares in the company is 580,000,000 including treasury shares.

Novo Nordisk expects to repurchase B shares worth DKK 10.0 billion during 2011. As of 9 September 2011, Novo Nordisk has repurchased a total of 12,767,053 B shares equal to a transaction value of DKK 7,732,712,169.

Novo Nordisk is a global healthcare company with 88 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs approximately 32,000 employees in 74 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on NASDAQ OMX Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com.

Further information:

Media:

Anne Margrethe Hauge
Tel: (+45) 4442 3450
amhg@novonordisk.com

Investors:

Klaus Bülow Davidsen
Tel: (+45) 4442 3176
klda@novonordisk.com

Frank Daniel Mersebach
Tel: (+45) 4442 0604
fdni@novonordisk.com

Lars Borup Jacobsen
Tel: (+45) 3075 3479
lbj@novonordisk.com

In North America:

Ken Inchausti
Tel: (+1) 609 514 8316
kiau@novonordisk.com

Jannick Lindegaard
Tel: (+1) 609 786 4575
jlis@novonordisk.com